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ABSTRACT
Background. Human herpesvirus (HHV) 5 and 6 remain latent after primary infection
and can be reactivated after immunosuppression for organ transplantation. An association
between HHV-5 and HHV-6 has been reported in liver transplant patients. The
coinfection is associated with clinical manifestations and graft dysfunction.
Objective. The aim of this study was to monitor herpesviruses in liver transplant
recipients to better understand issues involving coinfection with HHV-5/6 and correlations
with acute cellular rejection episodes and bacterial infections.
Methods. Forty-five adult liver transplant patients of median age 47 years (range,
18–66), gave blood samples and liver biopsies in the first 6 months after their surgeries.
Viremia was detected with the use of nested PCR and antigenemia; the Banff classification
was used to detect allograft rejection.
Results. IgG positive for HHV-5 was observed in 94% of subjects whose main indication
(67%) for transplantation was hepatitis C. Twenty-three (51.1%) displayed cytomeg virus
(CMV) infections and 12 (26.7%) HHV-6 infection. There were 6 patients (13.3%) with
HHV-5/6 coinfections. Eighteen of the 23 patients had CMV disease, showing a strong
correlation between a positive test and CMV disease; 6 displayed an acute cellular
rejection episode in the same period (2  6.62; P  .03). Four out of 6 patients who
displayed coinfections (HHV-5/6) had concomitant bacterial infections; 3/6 experienced
graft rejection episodes. During follow-up, 1 patient had HHV-6 infection diagnosed as
encephalitis followed by fever on the 24th day after surgery. The median 32 days for
HHV-6 detection by nested PCR positivity was shorter than 38 days for HHV-5.
Conclusions. HHV-5/6–infected patients displayed more allograft rejection episodes,
coinfections, and concomitant bacterial infections, besides an higher risk for CMV disease.
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sEight members of the Herpesviridae family have beenidentified as potential pathogens for humans. Their
prevalence among the adult population is 95%.1,2 Their
embers include HHV-5 and HHV-6.3 HHV-5 seropreva-
ence can varies from 40% to 60% among populations of a
igh socioeconomic level, and it is 80%–100% for popula-
ions at lower socioeconomic levels. These viruses are
niversal, remain latent after primary infection, and can be
eactivated with immunosuppression,2 as in organ trans-
lant patients. In liver transplant patients, HHV-5 (cyto-
egalovirus [CMV]) is the major cause of infection after
urgery; its prevalence is from 20% to 60%. Among patients
ith active infections, 80% develop clinical manifesta-
ions of the disease.3
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Transplantation Proceedings, 44, 2455–2458 (2012)HHV-6 infections occur among 14%–82% of solid organ
transplantations.4 There has been an association reported
etween HHV-5 and HHV-6 that results in clinical mani-
estations and graft dysfunction.4,5 Some studies have
hown that HHV-6 infection alters the host’s immune
ystem, reactivating HHV-5.6,7 Monitoring of these patients
by laboratory techniques allows an early sensitive diagnosis
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2456 SAMPAIO, GUARDIA, MILAN ET ALof infection/coinfection with these viruses. It is essential to
prevent clinical complications, graft rejection, and death.8,9
The aim of the present study was to monitor herpesvirus in
liver transplant recipients, seeking to better understand
issues involving HHV-5/6 coinfections, as well as correla-
tions with acute cellular rejection episodes and bacterial
infections.
METHODS
Forty-five adult patients of median age 47 years (range, 18–66)
who underwent liver transplantation from 2007 to 2009 were
prospectively included in this study with the approval of the Ethics
Committee and the Free Informed Consent term (number 430/
2003).
All patients underwent standard immunosuppressive therapy
based on calcineurin inhibitors cyclosporine (CyA, 4–8 mg/kg) or
tacrolimus (FK506, 0.1 mg/kg) plus steroids until day 180 after the
transplantation when they were tapered and withdrawn. The initial
CyA blood level was 200–400 ng/mL in the first 3 months and then
150–250 ng/mL for another month. The target FK506 blood level
was 8–12 ng/mL in the first 3 months and 5–10 ng/mL for another
month. Antiviral prophylaxis with acyclovir (200 mg every hours for
2 months) addressed herpes simplex. The patients received pro-
phylaxis for HHV-5 only when the donor was seropositive and the
recipient seronegative. Patients with CMV disease (clinical symp-
toms) received ganoclovir intravenously (10 mg/kg/d) for 6 weeks
followed by a maintenance dose.10
Collection of Blood Samples
The first sample was obtained at the moment of transplantation,
these, weekly for the first month, biweekly for the second month,
and once a month after day 90 until the end of the study (day 180).
Laboratory tests and liver biopsies were performed at the same
time.
Peripheral Blood Leukocyte DNA Extraction
The procedures for isolating blood leukocytes and DNA extraction
for CMV were as described previously with some modification.12
The amount and purity of DNA were determined by optical density
readings obtained with the use of spectrophotometry at a wave-
length of 260 nm (1 OD  50 ng). The final DNA concentration
resent in each sample was determined.2
CMV Nested PCR
Five microliters of DNA extracted from peripheral-blood leuko-
cytes, as described above, were used in nested polymerase chain
reaction (PCR). The reaction mixture contained primers specific
for CMV as generated after the previously described protocol with
some modifications. To exclude false-negative results, DNA sam-
ples were subjected to PCR with -globin primers.8,12,13
HHV-6 Nested PCR
Nested PCR was performed using 5 mL of DNA extracted from
serum as described above. The primers and protocol for HHV-6
nested PCR have been previously described.14 All amplifications
ere carried out on a Robocycler 40 (Stratagene, La Jolla, CA,
SA). Nested PCR products were analyzed under ultravioletight after electrophoresis in 2% agarose (Gibco-BRL, CA,SA) with ethidium bromide staining of the gels. All nested
CR reactions were performed in duplicate with second fresh
liquots.
CMV pp65-Antigenemia
Blood samples collected in EDTA-containing tubes were trans-
fered to the laboratory within 6 hours. Leukocytes were isolated
by a dextran sedimentation method, which was followed by
erythrocyte lysis. The cell pellet was suspended in phosphate-
buffered saline solution (PBS), and the polymorphonuclear
leukocytes (PML) were then centrifuged to prepare cytospin
slides (3  105 PML per slide). The slides were air dried and
xed in formaldehyde before being immunostained with mono-
lonal antibodies (Iq Products, The Netherlands) followed by
ncubation with peroxidase-labeled anti-mouse secondary anti-
ody (Biotest, Dreieich, Germany). The test was performed in
uplicate with results expressed as the number of positive cells
er 3  105 PML.15
CMV infection was defined as 2 consecutive positive nested-
PCR results and/or 1 positive antigenemia result and evidence of
HHV-5 replication regardless of symptoms (differs from latent
HHV-5).16 CMV disease was defined as evidence of HHV-5
nfection with attributable symptoms. HHV-5 disease was fur-
her categorized as a viral syndrome with fever, malaise, leuco-
enia, and thrombocytopenia or as a tissue-invasive disease.16
HHV-6 infection was defined as 1 positive nested-PCR result.
Coinfection was defined when 2 viruses were detected in the
same sample.
The diagnosis and monitoring of graft function for acute rejec-
tion episodes were performed according to the Banff International
Consensus.17 After all of the tests, we evaluated them with the
chi-square test and Yates correlation when necessary, as well as
basic statistics using Statistica 7.0.
RESULTS
HHV–5 positive IgG was observed in 94% of subjects
whose main indication for transplantation was hepatitis C
(67%). Twenty-three (51.1%) had concomitant CMV infec-
tions and 12 (26.7%) had HHV-6 infections. There were 6
(13.3%) with HHV-5/6 coinfections. Eighteen of the 23
patients with CMV infection had CMV disease, showing a
strong correlation between a positive test and CMV disease,
and 6 had acute cellular rejection in the same period (2 
.62; P  .03).
Four of the 6 patients who had HHV-5/6 coinfections
displayed concomitant bacterial infections, and 3 experi-
enced graft rejection episodes. One patient had HHV-6
infection as diagnosed by encephalitis followed by fever at
day 24 after surgery (Table I). The median time to detect
nested PCR positivity for HHV-6 was 32 days, which was
less than that for HHV-5 at 38 days.
DISCUSSION
Early detection of active viral replication helped to mini-
mize damage from HHV-5 disease with the use of rapid
sensitive laboratory tests.3,6,8,18
In this study we used antigenemia and nested PCR
techniques for HHV-5 and HHV-6 detection in peripheral
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HHV IN LIVER TRANSPLANTATION 2457blood. Antigenemia is a sensitive method to estimate viral
load with a good positive predictive value for the disease. It
can be detected several days before the appearance of
symptoms.8,9,11,18,19
In our study, HHV-5/6 coinfection after liver trans-
plantation showed clinical importance because of the
increased members of bacterial infections and acute
cellular rejection episodes. According to some au-
thors,4,19,20 the presence of an active replicating CMV
infection increases the risk of bacterial, fungal, viral, and
other superinfections as well as posttransplantation lym-
phoproliferative disease.
Concomitant infections for HHV-5 and HHV-6 are
generally associated with clinical manifestations. As re-
ported in other studies, HHV-6 infection can reactivate
HHV-5 or change the natural course of the disease.1,21
However, the clinical relevance of HHV-6 has not been
defined in transplant recipients.22
Some studies have shown that HHV-6 is associated with
neurologic disorders and encephalitis in liver transplanta-
tion.23,24 In the present study, there was 1 patient with
encephalitis associated with fever, who was also positive for
HHV-6, but the overall association was not significant. The
was not available for the HHV-6 DNA detection to confirm
the diagnosis. Therefore, the clinical hypothesis of enceph-
alitis was supported only by the presence of HHV-6 viral
DNA in peripheral blood.
Razonable21 has related the presence of allograft rejec-
ion per se to be one of the most potent inducers of CMV
eactivation, and therefore a significant risk factor for CMV
isease. Moreover, therapy for an allograft rejection epi-
ode with high levels of immunosuppression increases the
isk for CMV disease, creating a bidirectional relationship
etween CMV and cellular rejection.21,24 In our study, the
amples collected in the same period as the allograft
ejection showed a possible correlation between prior CMV
nd subsequent rejection.
In conclusion, the clinical impact can be demonstrated in
his study, where the CMV infected patients had more
llograft rejection, coinfections, and concomitant bacterial
Table 1. Distribution According to Cytomegalovirus (CMV)
Infection in 45 Cases
Yes No
Total(n  23, 51.1%) (n  22, 48.8%)
CMV disease* 16 (35.5%) 2 (4%) 18 (40%)
HHV-6 infection 6 (13%) 6 (13%) 12 (26.7%)
HHV-6 disease (?) 1 (2%) 0 (0%) 1 (2.2%)
Coinfection 5 (11.1%) 1 (2%) 6 (13.3%)
Bacterial infection* 17 (37.7%) 2 (4%) 18 (40%)
Acute cellular
rejection*
6 (13%) 0 (0%) 6 (13.3%)
?  encephalitis case.
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